Kuehne and Nagel’s Hyderabad Hub Sets New Standard for Indian Cold Chain Logistics

A new GDP-compliant logistics facility from Kuehne+Nagel in Hyderabad signals a structural shift in how temperature-sensitive pharmaceutical supply chains are managed out of one of India's most concentrated API and vaccine manufacturing corridors.

Kuehne+Nagel opens dedicated pharma logistics hub in Hyderabad

The facility, purpose-built for pharmaceutical and medical shipments, is positioned in Hyderabad, a city that accounts for a significant share of India's active pharmaceutical ingredient (API) and vaccine output. The location is not incidental: Hyderabad hosts a dense cluster of formulation and bulk drug manufacturers whose export volumes demand cold chain infrastructure that meets international GDP standards, including those aligned with WHO Technical Report Series 961 and EU GDP guidelines.

Kuehne+Nagel has framed the investment as a response to growing demand for specialised logistics solutions across the pharmaceutical and medical device sectors. The facility is designed to handle temperature-sensitive consignments, a category that has expanded sharply as biologics, vaccines, and specialty injectables constitute a larger proportion of Indian pharma exports.

Where Indian API exporters and MNC supply-chain leads should reassess cold chain risk

For supply-chain leads at multinational pharmaceutical companies sourcing APIs or finished dosage forms from Hyderabad, the facility introduces a credentialed option at the origin point, reducing the handoff risk that typically accumulates between manufacturing site and international freight. GDP compliance at the first-mile stage is increasingly a regulatory expectation, not a differentiator, particularly for shipments destined for EU or US markets where import alert exposure and GDP audit trails are standard.

Indian API exporters operating under pressure from USFDA and EMA inspection cycles will find the infrastructure relevant to their distribution control documentation. Demonstrating an unbroken, validated cold chain from Hyderabad manufacturing sites to export hubs is a recurring gap in regulatory submissions and CAPA responses.

How Hyderabad's logistics capacity develops through 2026

The broader build-out of pharma-grade logistics infrastructure in Hyderabad is likely to accelerate as India's API export volumes grow and as multinational companies diversify sourcing away from single-country dependencies. Kuehne+Nagel's facility sets a reference point for GDP-compliant cold chain at origin, a benchmark that competing logistics providers and domestic 3PLs operating in the corridor will be measured against.

Procurement and supply-chain teams at both Indian manufacturers and global pharma companies should track whether the facility pursues formal IATA CEIV Pharma certification, which would extend its credentialing to air freight lanes and further tighten the compliance envelope for high-value temperature-sensitive shipments.

The next visible checkpoint will be how the facility performs under GDP audit conditions as its first major export consignments move through international customs and regulatory review.